MetaVia

MetaVia is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing therapies for liver-related cardiometabolic disease. Formerly NeuroBo Pharmaceuticals, it renamed itself in November 2024 and now centres on two assets licensed from Korean manufacturer Dong-A ST: DA-1726, a once-weekly oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, and DA-1241 (vanoglipel), an oral GPR119 agonist being developed for MASH. DA-1726 reported a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at Day 109 in the Phase 1 Part 3B interim analysis presented in November 2026, and the company is planning a 48-week Phase 2 study in metabolic dysfunction and alcohol-associated liver disease. The company held roughly $12.6 million of cash at June 30, 2026, with Dong-A ST as its largest shareholder at 26.8%.